Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Clinical Microbiology Reviews
M A PfallerD J Sheehan

Abstract

Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between in vitro activity and outcome from both in vivo and clinical studies. Previously, the Subcommittee for Antifungal Testing of the Clinical and Laboratory Standards Institute (CLSI [formerly National Committee for Clinical Laboratory Standards]) proposed MIC interpretive breakpoints for fluconazole and Candida spp. These breakpoints were considered to be somewhat weak, because the clinical data supporting them came largely from mucosal infections and there were very few infections involving strains with elevated fluconazole MICs. We readdress the issue of fluconazole breakpoints for Candida by using published clinical and microbiologic data to provide further validation of the breakpoints proposed by the CLSI in 1997. We also address interpretive breakpoints for agar disk diffusion testing of fluconazole. The MIC distribution for fluconazole was determined with a collection of 13,338 clinical isolates. The overall MIC at which 90% of the isolates were inhibited was 8 microg/ml: 91% were susceptible (S) at a MIC of <or=8 microg/ml and ...Continue Reading

References

Aug 1, 1990·Connecticut Medicine·T Lubowski
Sep 1, 1986·Antimicrobial Agents and Chemotherapy·T E Rogers, J N Galgiani
Dec 1, 1988·Archives of Internal Medicine·S B WeyR P Wenzel
Dec 1, 1974·The Journal of Infectious Diseases·C M Metzler, R M DeHaan
Jun 1, 1995·The Journal of Antimicrobial Chemotherapy·J L Rodríguez-TudelaE Valencia
Aug 1, 1995·The Journal of Infectious Diseases·E J AnaissieG P Bodey
Jan 1, 1995·Antimicrobial Agents and Chemotherapy·J H RexM A Pfaller
Feb 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S ReddingM Pfaller
Mar 1, 1993·The Journal of Infection·W GraningerA Georgopoulos
Feb 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A M Sugar
Jun 1, 1997·Antimicrobial Agents and Chemotherapy·M E KlepserM A Pfaller
Dec 31, 1997·The Journal of Antimicrobial Chemotherapy·J D CartledgeB G Gazzard
Jun 13, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S ArikanS Unal
Jun 13, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S G RevankarT F Patterson
Jun 20, 1998·Clinical Microbiology Reviews·T C WhiteR A Bowden
May 21, 1998·Antimicrobial Agents and Chemotherapy·A LouieM H Miller
Sep 17, 1998·The Journal of Antimicrobial Chemotherapy·L W KitchenS P Day
Oct 3, 1998·Antimicrobial Agents and Chemotherapy·A S OrozcoS G Filler
Nov 25, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J R ReesA L Reingold
Jan 9, 1999·Clinical Microbiology Reviews·D J SheehanC M Sibley
Jun 5, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Voss, B E de Pauw
Aug 12, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M Cuenca-EstrellaJ L Rodríguez-Tudela
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A S KaoR A Hajjeh
Apr 1, 2000·Diagnostic Microbiology and Infectious Disease·D S BurgessM G Rinaldi
Feb 15, 2001·Diagnostic Microbiology and Infectious Disease·A Wong-BeringeraL Steele-Moore
Mar 27, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L G MillerJ E Edwards
May 8, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S WalmsleyS Richardson

❮ Previous
Next ❯

Citations

Apr 27, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E PintoL Salgueiro
Sep 22, 2007·Medical Mycology·Sevtap Arikan
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zeina A Kanafani, John R Perfect
May 13, 2009·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Blase BillackCesar Lau-Cam
Apr 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John F FisherCheryl A Newman
Jan 5, 2011·The Journal of Antimicrobial Chemotherapy·Manuel Cuenca-EstrellaThomas R Rogers
Dec 6, 2012·The Journal of Antimicrobial Chemotherapy·Gregory A EschenauerSimon W Lam
Oct 1, 2008·Critical Care Medicine·Andrew J LabelleMarin H Kollef
Mar 28, 2009·Critical Care Medicine·Simon W LamPeggy L Carver
Jul 2, 2008·Antimicrobial Agents and Chemotherapy·John W BaddleyDavid R Andes
Jul 25, 2007·Antimicrobial Agents and Chemotherapy·Juan L Rodríguez-TudelaManuel Cuenca-Estrella
Sep 24, 2008·Antimicrobial Agents and Chemotherapy·Luis Ostrosky-ZeichnerThomas J Walsh
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema
Feb 5, 2010·Journal of Clinical Microbiology·G Marshall LyonUNKNOWN Candida Surveillance Study Investigators
Dec 18, 2012·Journal of Clinical Microbiology·Stephen A Moser
May 21, 2010·Clinical Pharmacokinetics·Yanjun LiHartmut Derendorf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.